STOCKHOLM--(BUSINESS WIRE)--Regulatory News: Neurovive Pharmaceutical (STO:NVP): At the request of NASDAQ OMX Stockholm, the Company provides the following information regarding the license agreement referred to in the press release dated September 9, 2014. The license agreement has a term that may extend to the expiry of the patents that are the subject of the license agreement. Currently, the maximum term would extend to 2031, assuming no patent term extensions. The term could be shorter if the license agreement were terminated, such as for example, if the product demonstrates lack of efficacy or safety during development.
Help employers find you! Check out all the jobs and post your resume.
